Form 4: Regeneron Director Bassler Increases Equity Holdings

Regeneron Pharmaceuticals Director Bonnie L. Bassler acquired 155 restricted stock units and 1,962 non-qualified stock options.

Summary

• Bonnie L. Bassler, a Director at Regeneron Pharmaceuticals, Inc. (REGN), reported an acquisition of equity securities.
• On January 2, 2026, Bassler acquired 155 shares of Common Stock in the form of time-based vesting restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• Following this transaction, Bassler beneficially owns 1,703 shares of Common Stock directly.
• Also on January 2, 2026, Bassler acquired 1,962 non-qualified stock options with an exercise price of $772.76 per share.
• These stock options have an expiration date of January 2, 2036.
• A portion of these stock options will become exercisable on the date of the Issuer's first annual meeting of shareholders following the grant date, corresponding to the portion of one year that has passed from the grant date, with the remainder becoming exercisable on the first anniversary of the grant date.
• Following this transaction, Bassler beneficially owns 1,962 non-qualified stock options directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their equity holdings through grants, which generally indicates alignment of interests with shareholders and confidence in the company's future, even if it's part of a compensation package.

Positives

• The acquisition of restricted stock units and stock options by a director aligns their interests with those of the shareholders, as their personal wealth becomes more directly tied to the company's performance.

Future Outlook

The acquired restricted stock units are subject to time-based vesting. The non-qualified stock options will become partially exercisable on the date of the Issuer's first annual meeting of shareholders following the grant date, with the remainder becoming exercisable on the first anniversary of the grant date.

Industry Context

This filing represents a routine disclosure of insider transactions, specifically the grant of equity compensation to a director. Such grants are a common practice in the pharmaceutical industry and other sectors to incentivize and retain key personnel, aligning their long-term interests with company performance.

Stakeholder Impact

• Shareholders: The equity grants to a director can be seen as a positive signal, as it further aligns the director's financial incentives with the long-term performance and value creation for shareholders.

Next Steps

• Vesting of the 155 restricted stock units according to their time-based schedule.
• Vesting of the 1,962 non-qualified stock options, with a portion becoming exercisable after the first annual meeting following the grant date and the remainder on the first anniversary of the grant date.

Key Dates

Keywords

Regeneron, REGN, Form 4, insider transaction, stock options, restricted stock units, director compensation, equity grant